14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CLYM vs PLUR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLYM carries a Unified Composite Score of 45.7/100 (HOLD) at $9.64 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).
Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs PLUR. Trailing 12-month operating profitability (CLYM 0.0% vs PLUR -2454.5%) and valuation multiples (CLYM N/M vs PLUR 3.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CLYM vs PLUR Key Questions & Quantitative Answers
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLYM carries a Unified Composite Score of 45.7/100 (HOLD) at $9.64 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLYM leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $1.0M for PLUR. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.
PLUR screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus PLUR (-1022.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.